A multicentre, parallel group, randomised, double blind, placebo-controlled, phase II study evaluating the efficacy and safety of reperfusion thrombolytic therapy with intravenous recombinant tissue plasminogen activator (rtPA) for ischaemic stroke in patients on the non-vitamin K antagonist oral anticoagulant after reversing anticoagulant activity with the specific antidote
RecruitingCTIS2024-518509-17-00
Medical University Of GdanskAcute ischemic stroke
Start: 2022-01-10Target: 300Updated: 2024-12-09